People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spotlight Therapeutics, Inc. | — | Biotechnology | Series B | $61.6M | $687.7M | 2021 |
Krishna David Yeshwant at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Krishna David Yeshwant on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Blake Byers | 1 | 5 |
| Alexander Marson | 1 | 2 |
| Mary Haak-Frendscho | 1 | 2 |
| Blake David Byers | 1 | 1 |
| Alexander David Marson | 1 | 1 |
| Mary HaakFrendscho | 1 | 1 |
| Jacob Corn | 1 | 1 |
| Patrick David Hsu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.